Meningioma is a primary tumor of the central nervous system, most commonly found in the middle-aged and elderly. Most meningiomas are benign, whereas malignant meningiomas account for only 1% of all meningiomas. Meningiomas usually grow slowly, and patients often have headaches and epilepsy as the first symptoms. According to the location of the tumor, there can also be vision, visual field, olfactory, hearing impairment, and so on. Surgery is the main treatment. A case of giant malignant meningioma penetrating the skull is reported. The patient was a 67-year-old male with a left parietal scalp mass about 1 year ago, which gradually enlarged to the size of 6×6 cm and had no other symptoms. Imaging examination showed that the tumor eroded the skull, and the density was uneven. After surgical resection (Simpson grade I), poorly differentiated meningioma (World Health Organization Grade Ⅲ) was returned pathologically. After operation, the patient recovered well.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SCS.0000000000009436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cystic Basal Cell Carcinoma with a Giant Vulvar Cyst.
Acta Dermatovenerol Croat
November 2024
Takayuki Suyama, MD, PhD, Department of Dermatology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama, 343-8555, Japan; ORCID ID: 0000-0002-6986-411X.
Cystic basal cell carcinoma (BCC) is a rare subtype of BCC (1). Histologically, it is usually characterized by multiple small cysts without a clinical cystic appearance (2). Herein, we report an unusual case of cystic BCC with a large vulvar cyst.
View Article and Find Full Text PDFRare Coexistence: Giant Cell Tumor Recurrence and Infection in the Proximal Tibia - A Case Report.
J Orthop Case Rep
January 2025
Department of Orthopedics, Apollo sage hospitals, Bhopal, Madhya Pradesh, India.
Introduction: Giant cell tumor of bone (GCTB) ranks among the most prevalent locally aggressive tumor lesions, displaying a diverse range of biological behaviors. Recurrence of GCTB is well-documented, often attributed to microscopic tumour remnants remaining after intralesional curettage, with increased concern when infection occurs postoperatively. Studies suggest the limited effectiveness of adjuvants in preventing giant cell tumour recurrence, emphasizing the necessity of complete removal of malignant cells.
View Article and Find Full Text PDFGiant Cell Tumor of Distal Radius Treated with Wide Local Excision and Reconstruction with Ipsilateral Proximal Fibular Autograft - A Follow-Up.
J Orthop Case Rep
January 2025
Department of Orthopaedics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
Introduction: Giant cell tumour or osteoclastoma is benign, locally aggressive tumor with bone destruction and with malignant potential. It accounts for 5% of all primary bone tumor and occurs in skeletally mature individuals in the age group of 30 to 45 with peak incidence in the 3rd decade. GCT is more common in females.
View Article and Find Full Text PDFGiant Granular Cell Tumor of the Left Thigh, a Rare Case Report and Literature Review.
Orthop Res Rev
January 2025
Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, People's Republic of China.
Background: Granular cell tumor (GCT) is a rare soft tissue tumor characterized by Schwann cell differentiation. While GCT can occur in any part of the body, it is less common in the lower limbs. We report a case of a giant atypical GCT located in the left thigh, the tumor was initially small and painless at the time of discovery but gradually grew to 17 cm over a two-year period.
View Article and Find Full Text PDFDo Unresectable Giant Cell Tumors of Bone Treated With Denosumab Progress After Discontinuation of Treatment?
Cancer Rep (Hoboken)
January 2025
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Background: Denosumab represents a valuable treatment option for unresectable giant cell tumors of the bone (GCTBs). However, no standardized protocols exist determining the length of administration, with few studies having been published on patients who reached the end of treatment.
Aims: To analyze the outcomes of patients diagnosed with GCTB and who had finished single treatment with denosumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!